Ramosetron

Drug Profile

Ramosetron

Alternative Names: Irribow; Nasea; Ramosetron hydrochloride; YM 060

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Astellas Pharma
  • Class Antiemetics; Benzimidazoles; Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Irritable bowel syndrome; Nausea and vomiting
  • Phase II Postoperative nausea and vomiting

Most Recent Events

  • 26 May 2015 Registered for Irritable bowel syndrome (In adults, in females) in Japan (PO)
  • 26 May 2015 Registered for Irritable bowel syndrome (In adults, in females) in Japan (PO; disintegrating tablets)
  • 14 Jul 2014 Preregistration for Irritable bowel syndrome (in females) in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top